Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables (2018 - 2025)

Historic Receivables for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $16.8 million.

  • Zevra Therapeutics' Receivables rose 11618.74% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 11618.74%. This contributed to the annual value of $10.8 million for FY2024, which is 4181.92% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Receivables stood at $16.8 million, which was up 11618.74% from $18.3 million recorded in Q2 2025.
  • Zevra Therapeutics' Receivables' 5-year high stood at $18.6 million during Q4 2023, with a 5-year trough of $1.6 million in Q4 2021.
  • For the 5-year period, Zevra Therapeutics' Receivables averaged around $9.2 million, with its median value being $8.9 million (2024).
  • Examining YoY changes over the last 5 years, Zevra Therapeutics' Receivables showed a top increase of 47571.87% in 2022 and a maximum decrease of 7164.33% in 2022.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Receivables stood at $1.6 million in 2021, then skyrocketed by 475.72% to $9.4 million in 2022, then surged by 97.97% to $18.6 million in 2023, then tumbled by 41.82% to $10.8 million in 2024, then skyrocketed by 55.33% to $16.8 million in 2025.
  • Its Receivables was $16.8 million in Q3 2025, compared to $18.3 million in Q2 2025 and $12.6 million in Q1 2025.